| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Associated with MM development/progression, poor prognosis, and reduced responsiveness to bortezomib; may be involved in bortezomib resistance. |
| Molecular mechanism: |
Predicted ceRNA/sponging mechanism: bioinformatic prediction of interacting miRNAs and candidate mRNAs; pathway enrichment suggests involvement in PI3K-Akt, chemokine signaling, cell cycle, and cytokine-cytokine receptor interaction pathways. |
| Biological pathway or process: |
PI3K/AKT (other); chemoresistance (other); cell cycle (other); ceRNA regulation (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RNase R Treatment; RT-qPCR; Clinical Sample Validation; ROC Analysis; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Diagnostic biomarker (AUC 0.92); high expression associated with shorter OS and PFS; overexpression associated with poorer response to bortezomib. |
| Description: |
hsa_circRNA_101237 (hsa_circ_0003489; host gene CDK8) is significantly up-regulated in multiple myeloma bone marrow samples and MM cell lines, especially bortezomib-resistant cells. High hsa_circRNA_101237 is linked to worse prognosis (shorter OS/PFS) and poorer response to bortezomib, and bioinformatics suggests a potential circRNA-miRNA-mRNA regulatory network involving pathways such as PI3K-Akt and cell cycle. |
| Confidence score: |
0.636 |